Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) Clinical research trials and Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART). Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) clinical trial. Participants oftentimes recieve the most expert healthcare available for their Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART) condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "S" Clinical Trials Conditions > Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART)

Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART)



Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART)

For Condition: Carcinoma, Non-Small-Cell Lung,Brain Neoplasms,Metastases, Neoplasm
Status: Recruiting
Sponsor(s): Pharmacyclics ,
Synopsis: The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Adults (18 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; - KPS score of 70; - Each patient must sign a study-specific Informed Consent form Exclusion Criteria: - Liver metastases; - Extracranial metastases in two or more organs; - Known leptomeningeal metastases or subarachnoid spread of tumor; - Prior whole brain radiation; - Plan to use radiosurgery or radiation boost after completion of WBRT; - Planned chemotherapy during study treatment (prior and subsequent chemotherapy is allowed); - Prior total resection of a single brain metastasis; - Laboratory values as follows: LDH > 1.3 x upper limit of normal (ULN); ANC < 1500 /mm³; Platelets < 50,000 /mm³; Creatinine > 2.0 mg/dL; AST or ALT > 2 x ULN; Total bilirubin > 2 x ULN; - Women who are pregnant or lactating
Total Enrollment: 550

Location and Contact Information:


Additional Information:
Study ID Numbers:  PCYC-0211; 
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054795

Other Carcinoma, Non-Small-Cell Lung Studies:
1. Non-small cell lung cancer refractory to platinum-based therapy

2. ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.

3. Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients

4. This study is to assess the efficacy and safety of ZD6474 in subjects with Non-small cell lung cancer.

5. Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)

Related Studies:

Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Clinical Trials
Other Wien Clinical Trials

Study of Neurologic Progression with Motexafin Gadolinium and Radiation Therapy (SMART)
Modify your Search

  Other Carcinoma, Non-Small-Cell Lung Clinical Trials
  Other Clinical Trials
  Other Wien Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103